系统性硬化症相关间质性肺病肺生理结局测量工具选择:基于OMERACT Filter 2.1的系统综述
本研究采用OMERACT Filter 2.1流程,通过患者研究伙伴和工作组成员投票及系统文献综述,评估FVC和DLco在SSc-ILD中的测量性能。
要点
- FVC在SSc-ILD的RCT和纵向观察研究中获OMERACT工作组一致认可。
- DLco未达到OMERACT标准,不推荐在RCT中代表SSc-ILD肺生理。
核心结论
- FVC被认可用于SSc-ILD的随机对照试验和纵向观察研究。
- DLco基于现有证据未达到OMERACT标准,不推荐在RCT中代表SSc-ILD肺生理。
研究设计与样本
- 采用OMERACT Filter 2.1流程,包括患者研究伙伴和工作组投票及系统文献综述。
主要发现
- FVC的测量性能总结表显示五项测量属性均具高质量一致数据,支持认可。
- DLco的测量性能总结表显示缺乏重测信度数据且临床试验区分度证据不足。
- 投票工作组成员15人(100%)一致同意认可FVC。
关键数值与推荐
- FVC在构建效度、重测信度、纵向构建效度、临床试验区分度/敏感性和意义阈值五项属性上均有良好表现证据。
- DLco缺乏重测信度数据且临床试验区分度证据不足。
- OMERACT技术咨询组同意上述决定。
临床怎么用
- 在SSc-ILD的RCT和纵向观察研究中,可选用FVC作为肺生理结局测量工具。
- 不建议在SSc-ILD的RCT中使用DLco代表肺生理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) is a research organization focused on improving health care outcomes for patients with autoimmune and musculoskeletal diseases. The Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) Working Group on Lung Physiology is a group within OMERACT charged with identifying outcome measures that should be implemented in studies of patients with CTD-ILD. The OMERACT Filter 2.1 is an evidence-based algorithm used to identify outcome measures that are truthful, feasible, and able to discriminate between groups of interest. Our objective was to summate evidence (published literature, key opinion leader input, patient perspectives) that would influence the CTD-ILD Working Group's vote to accept or reject the use of two measures of lung physiology, the forced vital capacity (FVC) and the diffusion capacity of carbon monoxide (DLco) for use in randomized controlled trials (RTCs) and longitudinal observational studies (LOSs) involving patients with systemic sclerosis associated ILD (SSc-ILD). METHODS: Patient Research Partners (those afflicted with SSc-ILD) and the CTD-ILD Working Group on Lung Physiology were polled to assess their opinion on the FVC and DLco in terms of feasibility; the CTD-ILD Working Group was also queried on these instruments' face and content validity. We then conducted a systematic literature review to identify articles in the SSc-ILD population that assessed the following measurement properties of FVC and DLco: (1) construct validity, (2) test-retest reliability, (3) longitudinal construct validity, (4) clinical trial discrimination/sensitivity to detect change in clinical trials, and (5) thresholds of meaning. Results were summarized in a Summary of Measurement Properties (SOMP) table for each instrument. OMERACT CTD-ILD Working Group members discussed and voted on the strength of evidence supporting these two instruments and voted to endorse, provisionally endorse, or not endorse either instrument. RESULTS: Forty Patient Research Partners reported these two measures are feasible (are not an unnecessary burden or represent an infeasible longitudinal assessment of their disease). A majority of the 18 CTD-ILD Working Group members voted that both the FVC and DLco are feasible and have face and content validity. The systematic literature review returned 1,447 non-duplicated articles, of which 177 met eligibility for full text review. Forty-eight studies (13 RCTs, 35 LOSs) were included in the qualitative analysis. The FVC SOMP table revealed high quality, consistent data with evidence of good performance for all five measurement properties, suggesting requisite published evidence to proceed with endorsement. The DLco SOMP table showed a lack of data to support test-retest reliability and inadequate evidence to support clinical trial discrimination. There was unanimous agreement (15 [100%]) among voting CTD-ILD Working Group members to endorse the FVC as an instrument for lung physiology in RCTs and LOSs in SSc-ILD. Based on currently available evidence, DLco did not meet the OMERACT criteria and is not recommended for use in RCTs to represent lung physiology of SSc-ILD. The OMERACT Technical Advisory Group agreed with these decisions. CONCLUSION: The OMERACT Filter 2.1 was successfully applied to the domain of lung physiology in patients with SSc-ILD. The FVC was endorsed for use in RCTs and LOSs based on the Working Group's vote; DLco was not endorsed.
引用
- Roofeh D, Barratt SL, Wells AU, et al. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. Semin Arthritis Rheum. 2021. PMID: 34493396. doi:10.1016/j.semarthrit.2021.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。